Loading...

Purified anti-human HLA-A,B,C Antibody

Pricing & Availability
Clone
W6/32 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class I, MHC class I
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
a-W632_Purified_072607
Human peripheral blood lymphocytes were stained with purified anti-HLA-A,B,C (clone W6/32, filled histogram) or purified mouse IgG2a, κ isotype control (open histogram), followed by goat-anti-mouse IgG FITC.
  • a-W632_Purified_072607
    Human peripheral blood lymphocytes were stained with purified anti-HLA-A,B,C (clone W6/32, filled histogram) or purified mouse IgG2a, κ isotype control (open histogram), followed by goat-anti-mouse IgG FITC.
  • b-632_012105
    HEK293 cells were transfected with RelA or empty vector and 24hrs later cell extracts harvested using a 1% CHAPS lysis buffer. Extracts were resolved by non-denaturing, non-reducing electrophoresis, transferred to nitrocellulose, and probed with a 1:500 dilution purified W6/32 . Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and a chemiluminescence detection system. These data document that MHC class I was upregulated in cells constitutively expressing RelA. (Data was provided by Dr. Ezra Burstein, University of Michigan Medical School, Ann Arbor, MI).
Compare all formats
Cat # Size Price Quantity Check Availability Save
311402 100 µg 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8+ T cells. They play an important role in cell-mediated immune responses and tumor surveillance.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Cat, Cow, Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
Activ, Block, IHC-F, IP, WB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per 106 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21.

Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Darrow TL, et al. 1989. J. Immunol. 142:3329.
  2. Stern P, et al. 1987. J. Immunol. 138:1088.
  3. Tran TM, et al. 2001. Immunogenetics 53:440.
  4. Barbatis C, et al. 1981. Gut 22:985.
  5. Ayyoub M, et al. 2004. Cancer Immunity 4:7.
  6. DeFelice M, et al. 1990. Cell. Immunol. 126:420.
  7. Fayen J, et al. 1998. Int. Immunol. 10:1347.
  8. Turco MC, et al. 1988. J. Immunol. 141:2275.
  9. Geppert TD, et al. 1989. J. Immunol. 142:3763.
  10. Wooden SL, et al. 2005. J. Immunol. 175:1383.
  11. Nagano M, et al. 2007. Blood 110:151.
  12. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed
  13. Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed
  14. Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed
  15. Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed
  16. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  17. Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79.
  18. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope)
  19. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  20. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  21. Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations
  1. Mirlashari MR, et al. 2021. Transfusion. 61:1222. PubMed
  2. Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed
  3. Sim MJW, et al. 2022. Elife. 11: . PubMed
  4. Moon JS, et al. 2023. Nat Commun. 14:319. PubMed
  5. Zhu Z, et al. 2022. Front Oncol. 12:814312. PubMed
  6. Gallen C, et al. 2022. Vaccines (Basel). 10:. PubMed
  7. Fu J et al. 2019. Cell stem cell. 24(2):227-239 . PubMed
  8. Chen WT, et al. 2018. J Invest Dermatol. 138:1546. PubMed
  9. Khatri A, et al. 2023. JCI Insight. 8:. PubMed
  10. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  11. Jimenez-Duran G, et al. 2022. Front Immunol. 13:918551. PubMed
  12. Chou JM, et al. 2022. Front Microbiol. 13:883597. PubMed
  13. Nguyen R, et al. 2021. Cancer Immunol Immunother. 70:721. PubMed
  14. Tsuchiya N, et al. 2018. Oncoimmunology. 7:e1377872. PubMed
  15. Abdul–Salam VB, et al. 2019. Circ Res. 124:52:00. PubMed
  16. Hsiue EH, et al. 2021. Science. 371:. PubMed
  17. Andersen R, et al. 2018. Cancer Immunol Res. 0.404166667. PubMed
  18. Laing B, et al. 2010. J Thorac Cardiovasc Surg. 139:1402. PubMed
  19. Rennier K, et al. 2020. Clin Cancer Res. 26:5019. PubMed
  20. Wroblewska A et al. 2018. Cell. 175(4):1141-1155 . PubMed
  21. Willimsky G, et al. 2021. Elife. 10:. PubMed
  22. Garrido C, et al. 2018. JCI Insight. 3:e120121. PubMed
  23. Takeuchi M, et al. 2010. J Mol Cell Biol. 0.179861111. PubMed
  24. Mirandola L, et al. 2017. Oncotarget. 8:74378. PubMed
  25. Sharma M, et al. 2020. Front Immunol. 11:1136. PubMed
  26. Moquin-Beaudry G, et al. 2022. Cell Rep Methods. 2:100153. PubMed
  27. Parker R, et al. 2020. bioRxiv. . PubMed
  28. A A, et al. 2016. Biotechnol Bioeng. 112: 2214-27. PubMed
  29. Fitzgerald W, et al. 2018. Am J Reprod Immunol. 80:e12860. PubMed
  30. Gañán-Gómez I, et al. 2022. Nat Med. . PubMed
  31. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  32. Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed
  33. Higashi S, et al. 2022. J Cell Sci. 135:. PubMed
  34. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  35. Yumoto K, et al. 2016. Sci Rep. 6:36520. PubMed
  36. Ruiz Cuevas MV, et al. 2021. Cell Reports. 34(10):108815. PubMed
  37. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  38. Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed
  39. Han EX, et al. 2021. NPJ Regen Med. 6:40. PubMed
  40. Liu Y, et al. 2017. Clin Cancer Res. 23(2):514-522. PubMed
  41. Blees A, et al. 2017. Nature.. 10.1038/nature24627. PubMed
  42. Chen YL, et al. 2020. J Exp Med. 217:. PubMed
  43. Nöll A, et al. 2017. Proc Natl Acad Sci U S A. 114: E438 - E447. PubMed
  44. Makarkov AI, et al. 2019. NPJ Vaccines. 4:17. PubMed
  45. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  46. Neuperger P, et al. 2021. Cancers (Basel). 14:. PubMed
  47. Mujib S, et al. 2017. JCI Insight. 2:e93687. PubMed
  48. Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed
  49. McLoughlin R, et al. 2008. J Immunol. 181:1323. PubMed
  50. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
  51. Takahara M, et al. 2008. J Leukoc Biol. 83:742. PubMed
  52. Pettmann J, et al. 2021. eLife. 10:00. PubMed
  53. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  54. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
  55. Carlsten M, et al. 2019. Oncoimmunology. 8:e1534664. PubMed
  56. Nosaka K, et al. 2021. Anticancer Res. 41:4741. PubMed
  57. Jasmer B, et al. 2017. Oncotarget. 8:108643. PubMed
  58. Chen HC, et al. 2017. Immunol Cell Biol. 95:620. PubMed
  59. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
RRID
AB_314871 (BioLegend Cat. No. 311402)

Antigen Details

Structure
Ig superfamily
Distribution

All nucleated cells

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD8
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
3105 View all products for this Gene ID
UniProt
View information about HLA-A on UniProt.org

Other Formats

View All HLA-A,B,C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human HLA-A,B,C W6/32 FC
FITC anti-human HLA-A,B,C W6/32 FC
PE anti-human HLA-A,B,C W6/32 FC
PE/Cyanine5 anti-human HLA-A,B,C W6/32 FC
Purified anti-human HLA-A,B,C W6/32 FC,Activ,Block,IHC-F,IP,WB
Alexa Fluor® 488 anti-human HLA-A,B,C W6/32 FC
Alexa Fluor® 647 anti-human HLA-A,B,C W6/32 FC
Pacific Blue™ anti-human HLA-A,B,C W6/32 FC
PerCP anti-human HLA-A,B,C W6/32 FC
APC/Cyanine7 anti-human HLA-A,B,C W6/32 FC
PerCP/Cyanine5.5 anti-human HLA-A,B,C W6/32 FC
Ultra-LEAF™ Purified anti-human HLA-A,B,C W6/32 FC,Activ,Block,IHC-F,IP,WB
PE/Cyanine7 anti-human HLA-A,B,C W6/32 FC
Brilliant Violet 510™ anti-human HLA-A,B,C W6/32 FC
Alexa Fluor® 700 anti-human HLA-A,B,C W6/32 FC
PE/Dazzle™ 594 anti-human HLA-A,B,C W6/32 FC
Biotin anti-human HLA-A,B,C W6/32 FC
Brilliant Violet 605™ anti-human HLA-A,B,C W6/32 FC
APC/Fire™ 750 anti-human HLA-A,B,C W6/32 FC
TotalSeq™-A0058 anti-human HLA-A,B,C W6/32 PG
TotalSeq™-C0058 anti-human HLA-A,B,C W6/32 PG
TotalSeq™-B0058 anti-human HLA-A,B,C W6/32 PG
Spark NIR™ 685 anti-human HLA-A,B,C W6/32 FC
TotalSeq™-D0058 anti-human HLA-A,B,C W6/32 PG
GMP Ultra-LEAF™ Purified anti-human HLA-A,B,C SF W6/32 FC
GMP Ultra-LEAF™ Biotin anti-human HLA-A,B,C SF W6/32 FC
Spark UV™ 387 anti-human HLA-A,B,C W6/32 FC
Spark Red™ 718 anti-human HLA-A,B,C (Flexi-Fluor™) W6/32 FC
Spark Blue™ 574 anti-human HLA-A,B,C (Flexi-Fluor™) W6/32 FC
Spark Blue™ 550 anti-human HLA-A,B,C (Flexi-Fluor™) W6/32 FC
Go To Top Version: 3    Revision Date: 09.06.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account